FDA Fully Approves Retevmo for RET Fusion-Positive Medullary Thyroid Cancer

The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric ...

SEPTEMBER 30, 2024